Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

Summary

Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD

Timeline

Start

2018-10-15

Primary completion

2023-03

Completion

2025-12

Outcome

Met primary endpoint

release “The ADVANCE II study shows that DCP-001 induces sustained MRD conversion in a subset of patients with AML” mendus.com ↗

release “delivering a successful outcome on MRD conversions and control as the primary study endpoint” mendus.com ↗

Publications

• Background van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DCP-001	Vaccine	2.5e+07 cells	—
Subject	DCP-001	Vaccine	5e+07 cells	—

Indications